This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content

(Hypertension. 2002;39:721.)
© 2002 American Heart Association, Inc.

Awards

17th Annual Aventis Pharma Hypertension Research Clinical Fellowship Program Award

An extract of the first 250 words of the full text is provided, because this article has no abstract.

The purpose of this program and research award is to stimulate physicians-in-training to pursue a career in clinical research in hypertension. The research fellow must be conducting work in which he or she is the major senior investigator in any area of the researcher’s choice, including clinical or laboratory aspects of the hypertensive diseases. The fellow’s work would be supervised by the director of the research training program (the mentor), but the conduct of the investigation is primarily by the research fellow. The winning presentation receives $3,000, and the fellow’s mentor receives $25,000 to support the clinical investigative training of a research fellow the following year.

View larger version (101K): [in this window] [in a new window]   Dr Alberto Nasjletti (left) and Dr Richard A. Birnbaum (right)

Dr Richard A. Birnbaum completed his undergraduate work at the University of California, San Diego, and received his medical degree from the University of Louisville School of Medicine, Louisville, Ky. He completed his residency in internal medicine at the University of Colorado Health Sciences Center, Denver, Colo, and is currently a fellow in cardiology at the University of Virginia Medical Center, Charlottesville, Va. He spent the first 2 years of his fellowship in the laboratory of Coleen McNamara, studying the role of the basic helix-loop-helix factor E47 in vascular smooth muscle cell growth and vascular lesion formation. His work has led to the identification of E47 as an endogenous inhibitor of smooth muscle cell (SMC) growth, at least in part through regulation of the cdk inhibitor p21. Identification of E47 as a factor that . . . [Full Text of this Article]